Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Foeldvari

Showing results (101-110 of 174) with videos related to

Pageof 18
Sort By:
The Journal of Rheumatology|October 4, 2011
Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Otylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Clinical and Experimental Rheumatology|June 26, 2010
Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosisDoerte Huscher, David Pittrow, Oliver Distler, et al.
Rheumatology (Oxford, England)|May 4, 2023
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritisJelena Vojinović, Ivan Foeldvari, Joke Dehoorne, et al.
Clinical Immunology (Orlando, Fla.)|December 14, 2011
Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritisGregor Dueckers, Nihal Guellac, Martin Arbogast, et al.
Pediatric Rheumatology Online Journal|April 12, 2023
Adherence, helpfulness and barriers to treatment in juvenile idiopathic arthritis - data from a German Inception cohortSabine Kirchner, Jens Klotsche, Ina Liedmann, et al.
Arthritis Care & Research|May 23, 2023
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With AbataceptHermine I Brunner, Nikolay Tzaribachev, Ingrid Louw, et al.
Rheumatology (Oxford, England)|December 18, 2019
Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registryAriane Klein, Jens Klotsche, Boris Hügle, et al.
Rheumatology (Oxford, England)|November 4, 2020
Consensus-based recommendations for the management of juvenile systemic sclerosisIvan Foeldvari, Roberta Culpo, Francesca Sperotto, et al.
Arthritis Research & Therapy|August 31, 2024
Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritisHermine I Brunner, Grant S Schulert, Alyssa Sproles, et al.
Journal of Scleroderma and Related Disorders|May 19, 2017
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Pageof 18

Showing results (101-110 of 174) with videos related to

Sort By:
Pageof 18
The Journal of Rheumatology|October 4, 2011
Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Otylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Clinical and Experimental Rheumatology|June 26, 2010
Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosisDoerte Huscher, David Pittrow, Oliver Distler, et al.
Rheumatology (Oxford, England)|May 4, 2023
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritisJelena Vojinović, Ivan Foeldvari, Joke Dehoorne, et al.
Clinical Immunology (Orlando, Fla.)|December 14, 2011
Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritisGregor Dueckers, Nihal Guellac, Martin Arbogast, et al.
Pediatric Rheumatology Online Journal|April 12, 2023
Adherence, helpfulness and barriers to treatment in juvenile idiopathic arthritis - data from a German Inception cohortSabine Kirchner, Jens Klotsche, Ina Liedmann, et al.
Arthritis Care & Research|May 23, 2023
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With AbataceptHermine I Brunner, Nikolay Tzaribachev, Ingrid Louw, et al.
Rheumatology (Oxford, England)|December 18, 2019
Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registryAriane Klein, Jens Klotsche, Boris Hügle, et al.
Rheumatology (Oxford, England)|November 4, 2020
Consensus-based recommendations for the management of juvenile systemic sclerosisIvan Foeldvari, Roberta Culpo, Francesca Sperotto, et al.
Arthritis Research & Therapy|August 31, 2024
Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritisHermine I Brunner, Grant S Schulert, Alyssa Sproles, et al.
Journal of Scleroderma and Related Disorders|May 19, 2017
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosisDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Pageof 18